Best Options Strategy for GOSS
Looking for the best options strategy for Gossamer Bio, Inc. (GOSS)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live GOSS option chain right now, and a simple map from your view on GOSS to the strategy that fits it. Model any of them in the calculator before you trade.
About GOSS
Gossamer Bio, Inc. (GOSS) is a major company in Biotechnology. Options traders on GOSS tend to watch , since these can drive large moves in the share price.
About Gossamer Bio, Inc.
Gossamer Bio is a clinical-stage biopharmaceutical company developing targeted therapies for rare lung diseases. Its main asset is GB002, an inhaled medication that works by inhibiting multiple receptor pathways involved in disease progression. The compound targets PDGFR, CSF1 receptor, and c-KIT and is currently in Phase 3 trials for pulmonary arterial hypertension, a serious condition affecting the lungs and heart. The company operates under a license agreement with Pulmokine, Inc., which grants it rights to develop and commercialize GB002 along with backup candidate compounds.
Gossamer Bio generates revenue and value primarily through its clinical pipeline and licensing arrangements. As a clinical-stage company without approved products yet, it operates in the rare disease space where treatments address significant unmet medical needs and often command premium pricing. The company is based in San Diego and has structured its business model around partnership arrangements that help fund development costs while maintaining commercial rights to its leading therapy.
Today's top-scoring strategy for GOSS
Our engine ranks defined-risk strategies on the live GOSS chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 100× | STOCK | — | $0.15 |
| Sell | 1× | CALL | $1.5 | $0.02 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $0 | $6 | $6 | $6 | $6 | $6 |
| $0 | $5 | $5 | $5 | $5 | $5 |
| $0 | $4 | $4 | $4 | $4 | $4 |
| $0 | $3 | $3 | $3 | $3 | $3 |
| $0 | $3 | $3 | $3 | $3 | $3 |
| $0 | $2 | $2 | $2 | $2 | $2 |
| $0 | $1 | $1 | $1 | $1 | $1 |
| $0 | $1 | $1 | $1 | $1 | $1 |
| $0 | −$0 | −$0 | −$0 | −$0 | −$0 |
| $0 | −$1 | −$1 | −$1 | −$1 | −$1 |
| $0 | −$2 | −$2 | −$2 | −$2 | −$2 |
Live scan from 2026-07-20 · quotes delayed ~15 minutes
Historical backtest: how a Covered Call on GOSS would have performed
We approximated a Covered Call on GOSS, entered repeatedly over the past year (92 historical entries, each held to expiration) with Black-Scholes-modelled entry premiums. Here is how that would have played out on real GOSS price history — an educational backtest, not a prediction of future returns.
Approximate: entry premiums are modelled with Black-Scholes from trailing realised volatility, held to expiration and settled against the real historical close. Real fills, implied volatility and slippage differ — treat it as directional context, not exact returns.
Implied volatility
GOSS is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 171% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on GOSS currently price in about 171% implied volatility, versus roughly 166% the stock has actually realised over the past month. The two are roughly in line, so neither buying nor selling premium has a clear volatility edge here.
Off that volatility, the options market is pricing a move of about ±$0.07 (±50%) in GOSS by 2026-08-21 — a range of roughly $0.07 to $0.22. Strikes inside that band hold most of the premium and see most of the action.
GOSS options chain highlights: open interest, volume and skew
The live GOSS options chain shows a put/call open-interest ratio of 0.14 (bullish-leaning (more calls)), with at-the-money implied volatility near 50%.
Snapshot of open interest, volume and implied volatility for the nearest scanned expiration — context, not a trading signal.
Earnings & IV crush
GOSS's next earnings report is due around November 4, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $87M
- Beta (vs market)
- 2.01
- 52-week range
- $0.11–$3.87 (1% up the range)
- Short interest
- 15.2% of float · 4.0 days to cover
With 15.2% of GOSS's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
Other strong setups for GOSS
If your view on GOSS differs, these also scored well in the latest scan:
How to choose an options strategy for GOSS
Start with your outlook on GOSS, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while GOSS stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open GOSS in the free calculator →
Frequently asked questions
What is the best options strategy for GOSS?
It depends on your outlook. Bullish traders often use a long call or bull call spread on GOSS; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are GOSS options liquid enough to trade?
Gossamer Bio, Inc. (GOSS) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade GOSS options?
Buying a single GOSS call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade GOSS or any security. Do your own research.
What does Gossamer Bio, Inc. do?
Gossamer Bio, Inc. (GOSS) operates in the Biotechnology industry. The "About Gossamer Bio, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Gossamer Bio, Inc. pay a dividend?
We don't show a confirmed dividend yield for Gossamer Bio, Inc. here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.
When does Gossamer Bio, Inc. next report earnings?
Gossamer Bio, Inc.'s next earnings are expected around November 4, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Price trend
Tickers related to GOSS
Comparing GOSS with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 3115 Merryfield Row, Suite 120, San Diego, CA, 92121, United States
- Industry
- Biotechnology
- Employees
- 161
- CEO
- Mr. Faheem Hasnain
- Phone
- 858 684 1300
- Website
- www.gossamerbio.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.